- Home
- CARM vs TLPH Comparison
CARM vs TLPH Comparison
Compare CARM & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- TLPH
- Stock Information
- Founded
- CARM 2016
- TLPH 2005
- Country
- CARM United States
- TLPH United States
- Employees
- CARM N/A
- TLPH N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- TLPH Health Care
- Exchange
- CARM Nasdaq
- TLPH Nasdaq
- Market Cap
- CARM 12.2M
- TLPH 11.1M
- IPO Year
- CARM N/A
- TLPH 2011
- Fundamental
- Price
- CARM $0.37
- TLPH $0.93
- Analyst Decision
- CARM Hold
- TLPH Strong Buy
- Analyst Count
- CARM 5
- TLPH 1
- Target Price
- CARM $0.90
- TLPH $6.00
- AVG Volume (30 Days)
- CARM 25.7M
- TLPH 7.3M
- Earning Date
- CARM 11-06-2025
- TLPH 11-12-2025
- Dividend Yield
- CARM N/A
- TLPH N/A
- EPS Growth
- CARM N/A
- TLPH N/A
- EPS
- CARM N/A
- TLPH N/A
- Revenue
- CARM $10,767,000.00
- TLPH $27,000.00
- Revenue This Year
- CARM N/A
- TLPH N/A
- Revenue Next Year
- CARM N/A
- TLPH $14,533.26
- P/E Ratio
- CARM N/A
- TLPH N/A
- Revenue Growth
- CARM N/A
- TLPH N/A
- 52 Week Low
- CARM $0.14
- TLPH $0.38
- 52 Week High
- CARM $1.27
- TLPH $1.20
- Technical
- Relative Strength Index (RSI)
- CARM 55.76
- TLPH 79.40
- Support Level
- CARM $0.34
- TLPH $0.40
- Resistance Level
- CARM $0.44
- TLPH $1.07
- Average True Range (ATR)
- CARM 0.05
- TLPH 0.13
- MACD
- CARM 0.01
- TLPH 0.05
- Stochastic Oscillator
- CARM 47.28
- TLPH 61.44
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.